Chronic Diseases News
-
Showcase
AioCare system could be successfully applied in primary healthcare Centers.
The role of spirometry in diagnosing and monitoring chronic obstructive airway diseases is crucial. According to WHO, the demonstration of irreversible airway obstruction is essential for diagnosing chronic obstructive pulmonary disease (COPD), which is the third leading cause of death worldwide. It is estimated that up to 67–81% of patients with COPD remain undiagnosed. Mobile phone-linked ...
By AioCare
-
Showcase
New device offers a mouthful of data for chronic diseases
Aidar Health, formerly known as Multisensor Diagnostics, has developed a portable hand-held device that allows patients to measure and track vital signs in a matter of seconds. Roughly the size of an iPhone, MouthLab consists of a hand unit and a mouthpiece that fits between the teeth and lips. The mouthpiece uses special sensors to gather information from breathing patterns, saliva and blood ...
By Aidar Health
-
AI Stocks Targeting Opportunities in the Global Healthcare Market (OTCQB: AVAI) (NASDAQ: NVDA) (NYSE: DELL) (NASDAQ: OTRK)
Investorideas.com, a global news source and expert investing resource covering AI stocks issues a news snapshot looking at how AI plays a key role in the future of healthcare, featuring Avant Technologies, Inc. (OTCQB: AVAI), an artificial intelligence (AI) technology company specializing in creating and developing innovative and advanced AI infrastructure solutions. What is the opportunity for ...
-
Empowering Patient Care: Global Medical Kiosks Market Poised for Remarkable 14.8% CAGR, According to BCC Research
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a thorough analysis of its current landscape and future ...
By BCC Research
-
CD Formulation Newly Launches Dissolving Microneedle Preparation Services: Enhancing Drug Delivery Efficiency
CD Formulation, a leading provider of contract pharmaceutical formulation development services, recently announced the launch of its dissolving microneedle preparation services. This breakthrough in drug delivery technology promises to revolutionize the way medications are administered, enhancing efficiency and patient comfort. Microneedles are tiny, painless needles that penetrate the skin's ...
-
Vantage Welcomes Roczen!
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
-
Pushing the Boundaries of Drug Delivery: CD Formulation's Breakthrough Microsphere and Microneedle Technologies
As medicine continues to advance in this new era, drug delivery methods have been revolutionized to enhance patient comfort, improve treatment outcomes and ensure effective delivery of therapeutic compounds. CD Formulation, a leading pharmaceutical research and development company, has recently unveiled a series of cutting-edge technologies that will further revolutionize and redefine the realm ...
-
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
By Bayer AG
-
Analysis of the cryolipolysis slimming machine advantages and disadvantages
Cryolipolysis is a medical aesthetic technique that uses freezing to break down excess fat in the body to achieve a slimming effect. This technique has a great popularity and many people feel confident and beautiful because of the success of this technique to lose weight. As we all know, the medical aesthetic industry has always been a hot industry and cryolipolysis beauty machine as a technique ...
-
New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...
By Bayer AG
-
Why Knowledge Is Power In The Treatment Of Obesity
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
-
Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies. The company plans to continue growing its team to power the expansion of Juvena’s ...
-
Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
By Bayer AG
-
Endosomal Signaling Of Delta Opioid Receptors Is An Endogenous Mechanism And Therapeutic Target For Relief From Inflammatory Pain
Whether G protein-coupled receptors signal from endosomes to control important pathophysiological processes and are therapeutic targets is uncertain. We report that opioids from the inflamed colon activate δ-opioid receptors (DOPr) in endosomes of nociceptors. Biopsy samples of inflamed colonic mucosa from patients and mice with colitis released opioids that activated DOPr on nociceptors to ...
-
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
By Bayer AG
-
Alex MacKerell, PhD, SilcsBio Co-founder & CSO, Co-Leads Study on Use of SILCS Technology to Improve Lung Disease Treatments
December 14, 2022, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced its Co-Founder and Chief Scientific Officer, Alexander D. MacKerell Jr., PhD, has co-led a study focusing on improving respiratory treatments via SilcsBio’s Site Identification by Ligand Competitive Saturation (SILCS) ...
-
Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are thrilled to receive this investment, which raises Third Pole Therapeutics’ series B financing and commitments to date to over $85M. I am ...
-
LISCure`s Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be ...
-
Portal Instruments appoints Dr. Veena Rao, PhD, as Chief Business Officer
Portal Instruments is pleased to announce the appointment of Dr. Veena Rao, PhD, as Chief Business Officer, effective December 5th, 2022. Dr. Rao will lead the identification, evaluation, and negotiation of partnership opportunities for Portal. In addition, Dr. Rao, in close collaboration with the CEO and cross-functional team, will guide the company’s short and long-term commercial ...
-
Bodyport Appoints Amit Rushi as Chief Commercial Officer and Phyllis Whiteley, Ph.D. as Chair of the Board of Directors
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you